Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease is a research paper published in New England Journal of Medicine (2021). On theSindex it has a DataRank of 4.7. It has been cited 664 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.975
From this paper's citation signal
Citation Network Contribution
3.8
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NCI NIH HHS
Grant: U01 CA236489
Intramural NIH HHS
Grant: ZIA BC011920
Medical Research Council
Grant: MR/T024097/1
National Institutes of Health
Grant: 2U01CA236489-05A1
Developing a Translation Pipeline for VHL Mutant Malignancies
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
FWCI
32.51
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals